Identification of α1A-adrenoceptor selective antagonists for the treatment of benign prostatic hyperplasia

Drugs of the Future

Volumn 26, Issue 8, 2001, Pages 757-765

  Lagu, B ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 2 (2 AMINOETHOXYMETHYL) 6 ETHYL 1,4 DIHYDRO 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 AMIDE 3 [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE; 4 (3,4 DIFLUOROPHENYL) 6 ETHYL 3,4 DIHYDRO 2(1H) OXO 3,5 PYRIMIDINEDICARBOXYLIC ACID 5 AMIDE 3 [3 (4 METHOXYCARBONYL 4 PHENYL 1 PIPERIDINYL)PROPYL]AMIDE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; DIHYDROPYRIDINE DERIVATIVE; NIGULDIPINE; OXAZOLIDINONE DERIVATIVE; TERAZOSIN; UNCLASSIFIED DRUG;

CHEMICAL MODIFICATION; DRUG STRUCTURE; PROSTATE HYPERTROPHY; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034783196     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.08.662740     Document Type: Review

References (49)

1. Benign prostatic hyperplasia: A review of its histogenesis and natural history
2. The origin and development of benign prostatic hyperplasia. An age dependent Process
3. Nonoperative management of benign prostatic hyperplasia
4. Pharmacological options in the treatment of benign prostatic hyperplasia
5. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia
6. Doxazosin for benign prostatic hyperplasia: Long term efficacy and safety in hypertensive and normotensive patients
7. Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation
8. 1-adrenoceptors in vascular smooth muscle
9. 1-adrenergic receptor subtypes in human prostate
10. 1c-subtype
11. 1c-Adrenergic antagonists and orthostatic hypotension in the rat
12. 1A-adrenergic receptor antagonists
13. 1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia
14. 2+ channel antagonist niguldipine
15. 1-antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery
16. 1A-adrenoceptor selective antagonist that inhibits phenylephrine-induced contraction of the human prostate
17. 1A-adrenoceptor selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia
18. 1A-radioligand, to rat and human tissues
19. A double protection strategy for the synthesis of 3,5-disubstituted dihydropyridines
20. 1A-antagonists
21. 1A-adrenoceptor selective antagonists: Structure-activity relationships of dihydropyrimidinones
22. 1A-adrenoceptor selective antagonists: Structure-activity relationship in dihydropyrimidines
23. Dihydropyrimidine calcium channel blockers: 2-Heterosubstituted 4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines
24. 1A-adrenoceptor selective antagonists: Approaches to eliminate opioid active metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine
25. 1A-receptor antagonists
26. 1A-adrenoceptor selective antagonists
27. 1A-adrenoceptor selective antagonists: Approaches to eliminate opioid active metabolite by using phenylpiperazine containing side chains
28. 1a-selective antagonists: 7. Modification of the piperidine moiety into 4-aminocyclohexane; identification and structure-activity relationship of SNAP 6991 analogs
29. 1A-selective adrenergic receptor antagonist
30. 1A-receptor antagonists for the treatment of benign prostatic hyperplasia
31. 1A-adrenergic receptor antagonist
32. 1a-receptor subtype
33. 1A-antagonist on urinary flow rate in men with symptomatic BPH
34. 1A-adrenergic receptor antagonist, in presence of human liver microsomes: Major role for the cytochrome P450 3A (CYP3A) subfamily
35. 1A-adrenergic receptor antagonist with high oral bioavailability
36. 1A-selective adrenoceptor antagonist
37. 1A-adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones
38. 1A-adrenergic receptor antagonists
39. 1A-adrenergic receptor antagonists. Effects of pharmacophore regio- and stereochemistry on potency and selectivity
40. 1A-adrenergic receptor antagonists